Form 8-K Verve Therapeutics, Inc. For: Apr 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Verve Therapeutics (VERV) PT Lowered to $40 at Stifel
April 2, 2024 4:52 PM EDTStifel analyst Dae Gon Ha lowered the price target on Verve Therapeutics (NASDAQ: VERV) to $40.00 (from $56.00) while maintaining a Buy rating.
The analyst comments "Shares are sharply lower following an earlier VERVE-101 update (LINK) likely amplified by the small dataset backing the... More
